Core Laboratories Inc (CLB)

Wall St is expecting 0.13 EPS for $CLB Q1 [Reporting 04/29 AMC] http://www.estimize.com/intro/clb?chart=historical&metric_name=eps&utm_cont

$CLB (-3.6% pre) Core Laboratories (NYSE: CLB) trims Q1 2026 guidance amid Middle East turmoil https://ooc.bz/l/97007

PickAlpha Evening Insights | 2026-03-23 - Trade Ideas For Tomorrow 1/3 Short $CLB — Tactical (1–5d) • Earnings Plan: Short CLB at next regular-session open to capture guidance-cut repricing over the next 1–3 sessions. Core Laboratories cut Q1 2026 guidance after the close, now expecting USD 119–123 mn revenue, much lower operating income and EPS of USD 0.05–0.07, citing Middle East conflict, customer delays and supply-chain disruptions. This directly undermines near-term earnings expectations and margins. Oilfield-services names typically reprice sharply to such negative pre-announcements, creating a tactical short opportunity in CLB. Risk: Exit if CLB closes above its next-session open on the next two sessions. • Valid until 2026-03-30 close (ET) Trade credibility: actionability ★★★★☆ | timeliness ★★★★☆ | clarity ★★★★☆

$APO $BARK $BNGO $CLB $AARD AFTER-HOURS MOVERS: Currently Higher After Earnings: - BARK (BARK) up 9.5% - Bionano Genomics (BNGO) up 2.1% Currently Lower After Earnings/Guidance: - Core Laboratories (CLB) down 4.6% after Q1 pre-announcement - Aardvark Therapeutics (AARD) down 1.5% Currently Also Lower: - Comtech Telecommunications (CMTL) down 0.6% after equity offering - Apollo Global Management (APO) down 2.6% after Bloomberg report of capped private equity redemptions

$CLB Core Laboratories sees Q1 EPS 5c-7c, two estimates 15c Sees Q1 revenue $119M-$123M, two estimates $125.4M. The company states: "At this time, due to regional instability, including client-driven project delays, travel constraints, and supply-chain disruptions, the Company expects first quarter 2026 revenue and earnings to be below its previously issued guidance provided on February 4, 2026. Changes in client activity levels across the Middle East are directly impacting operations in the countries where Core Lab operates. Damage to oil refining infrastructure and storage terminals has created capacity limitations, forcing operators to shut in or limit oil production. These effects have extended to regional supply chains and the maritime transportation of crude oil and refined products-particularly through the Strait of Hormuz-resulting in logistical constraints and delays in project execution. The impact has been more pronounced in Reservoir Description due to its unique role in supporting regional client studies, crude oil assay testing, and reservoir rock and fluid characterization, all of which rely on predictable field access, sample movement, and laboratory operations. Production Enhancement has been comparatively less affected; however, shipments of energetics products into certain parts of the region have been delayed or temporarily suspended."

$CLB I wonder what oil services companies are going to make all these repairs and restarts for wells and drilling? $BOOM

$CLB RSI: 17.50, MACD: -0.6776 Vol: 1.04, MA20: 17.23, MA50: 18.22 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

$CLB firing on all cylinders overseas… but can it outrun U.S. headwinds? Strong international demand, solid free cash flow generation, and a healthy financial position paint a fundamentally sound picture. But near-term U.S. land activity challenges and margin pressure could cap upside in the short run ⚠️ Is this a buy on strength or a wait-and-see setup? Full breakdown here 👉 https://www.zacks.com/stock/news/2871026/core-labs-jumps-79-in-6-months-time-to-buy-or-stay-on-the-sidelines?cid=sm-stocktwits-2-2871026-teaser-33926&ADID=SYND_STOCKTWITS_TWEET_2_2871026_TEASER_33926

$CLB: Riding High but Is the Momentum Sustainable? 🚀 Core Laboratories has surged 78.8% over the past six months, outperforming its peers and the broader sector. Strong international demand is driving revenue growth, but investors should note the premium P/E ratio and potential headwinds from U.S. market softness and tariff pressures. Is now the right time to buy, or should you wait for a dip? Full analysis here 👉 https://www.zacks.com/stock/news/2871026/core-labs-jumps-79-in-6-months-time-to-buy-or-stay-on-the-sidelines?cid=sm-stocktwits-2-2871026-body-33920&ADID=SYND_STOCKTWITS_TWEET_2_2871026_BODY_33920

$CLB just put numbers on the board for Q1 2026 — and the range matters. 👀 Management expects revenues between $124M and $130M, with earnings per share guided to 11–15 cents for the first quarter of 2026. Clear targets, clear expectations. See the full outlook and what’s driving the range 👉 https://www.zacks.com/stock/news/2836069/core-laboratories-q4-earnings-beat-estimates-expenses-increase-yy?cid=sm-stocktwits-2-2836069-teaser-32287&ADID=SYND_STOCKTWITS_TWEET_2_2836069_TEASER_32287